233 related articles for article (PubMed ID: 31714285)
1. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar MJB; van Raalte DH
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
[TBL] [Abstract][Full Text] [Related]
2. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
[TBL] [Abstract][Full Text] [Related]
3. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M
Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
[TBL] [Abstract][Full Text] [Related]
4. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
5. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
Mima A; Nomura A; Fujii T
Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
[TBL] [Abstract][Full Text] [Related]
6. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
Mora PF; Johnson EL
Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
[TBL] [Abstract][Full Text] [Related]
7. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Pieters IC; Cahen DL; Diamant M; van Raalte DH
BMJ Open; 2015 Nov; 5(11):e009579. PubMed ID: 26586327
[TBL] [Abstract][Full Text] [Related]
9. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
11. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
Kawanami D; Matoba K; Sango K; Utsunomiya K
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
[TBL] [Abstract][Full Text] [Related]
12. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
13. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
Davies MJ; Bianchi C; Del Prato S
Metabolism; 2020 Jun; 107():154242. PubMed ID: 32315698
[TBL] [Abstract][Full Text] [Related]
14. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
15. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet MH; Smits MM; Morsink LM; Diamant M
Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
[TBL] [Abstract][Full Text] [Related]
16. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
17. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
